NEW YORK (Reuters Health)—The oral Janus kinase (JAK) inhibitor tofacitinib appears to improve moderate to severe nail psoriasis, according to a new study. “Nails are hard to treat in psoriasis and we need better treatments,” says Dr. Luis Garza, a dermatologist at Johns Hopkins School of Medicine in Baltimore, who was not involved in the research….
EMA Panel Recommends Nod for Sanofi, Regeneron’s Arthritis Drug
(Reuters)—A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron’s experimental drug to treat rheumatoid arthritis (RA). The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, sarilumab (Kevzara), citing its ability to reduce the signs and symptoms of RA. Sarilumab, the active…
Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
A recent study examined the relationship between complement activation and coronary artery disease in patients with rheumatic disease. Researchers found these patients had higher plasma terminal complement complexes and more complement activation in the vascular adventitia, which may accelerate cardiovascular disease and act as a target for new therapies…
Valeant Prices Psoriasis Treatment at $3,500 Per Month
(Reuters)—Canadian drug maker Valeant Pharmaceuticals International Inc. said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017. Brodalumab (Siliq) is the lowest priced injectable biologic psoriasis treatment currently on the market, Valeant says. Drugmakers are facing intense criticism from…
Maximizing the ACR’s Power: A conversation with Rheumatology Research Foundation President Eric Matteson, MD, MPH
In preparing for the second year of his term leading the Rheumatology Research Foundation, Eric Matteson, MD, MPH, has developed an ambitious set of goals for the year ahead, and he says the strong professional and personal inspiration he gets from serving in various volunteer roles within the College is what helps drive him to…
NKTR-181 Promising for Chronic Low Back Pain
NKTR-181, a mu-opioid agonist analgesic, has proved safe and effective for treating chronic low back pain vs. placebo in a recent clinical trial…
A Moving Target: Cardiovascular Risk & Rheumatic Disease
For patients with rheumatic disease, general treatment guidelines for managing cardiovascular risk are suboptimal, says Katherine Liao, MD. A patient’s level of disease activity and inflammation affect their risk…
Tocilizumab Effectively Treats Early RA for Up to Two Years
NEW YORK (Reuters Health)—Patients with early rheumatoid arthritis (RA) treated with IV tocilizumab alone or with methotrexate maintained clinical benefits during their second year of treatment, researchers say. Sophie Dimonaco of Roche Products Ltd. in Welwyn Garden City, UK and colleagues sought to determine whether the efficacy and safety of IV tocilizumab, as demonstrated in…
Studies Highlight Risk of Damage from Lupus Treatments
WASHINGTON, D.C.—Conference goers who braved the final day of the 2016 ACR/ARHP Annual Meeting were awarded for their stamina by learning about issues relating to the damage caused by systemic lupus erythematosus (SLE) during the session Systemic Lupus Erythematosus—Clinical Aspects and Treatment V: Damage and Morbidity. Minimizing Damage: Early Use of GC-Sparing Strategies Jayne Little,…
Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus
WASHINGTON, D.C.—Experts at the 2016 ACR/ARHP Annual Meeting session, Systemic Lupus Erythematosus—Clinical Aspects and Treatment IV: Biomarkers, reported on a number of recent studies showing advancement in our understanding of the disease mechanisms underlying systemic lupus erythematosus (SLE) that place these patients at risk for cardiovascular disease (CVD) and other comorbidities. Mechanisms of CVD Risk…
- « Previous Page
- 1
- …
- 432
- 433
- 434
- 435
- 436
- …
- 816
- Next Page »